Method and system for microbiome-derived diagnostics and therapeutics

    公开(公告)号:US10289805B2

    公开(公告)日:2019-05-14

    申请号:US15621144

    申请日:2017-06-13

    申请人: uBiome, Inc.

    摘要: A method for diagnosing and treating an immune microbial dysfunction in a subject, the method comprising: receiving an aggregate set of biological samples from a population of subjects; generating at least one of a microbiome composition dataset and a microbiome functional diversity dataset for the population of subjects; generating a characterization of the immune microbial dysfunction based upon features extracted from at least one of the microbiome composition dataset and the microbiome functional diversity dataset, wherein the characterization is diagnostic of at least one of Crohn's disease, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), ulcerative colitis, and celiac disease; based upon the characterization, generating a therapy model configured to correct the immune microbial dysfunction; and at an output device associated with the subject, promoting a therapy to the subject based upon the characterization and the therapy model.

    Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues

    公开(公告)号:US10268803B2

    公开(公告)日:2019-04-23

    申请号:US15621168

    申请日:2017-06-13

    申请人: uBiome, Inc.

    摘要: A method for at least one of characterizing, diagnosing and treating a neurological health issue in at least a subject, the method comprising: receiving an aggregate set of biological samples from a population of subjects; generating at least one of a microbiome composition dataset and a microbiome functional diversity dataset for the population of subjects; generating a characterization of the neurological health issue based upon features extracted from at least one of the microbiome composition dataset and the microbiome functional diversity dataset; based upon the characterization, generating a therapy model configured to correct the neurological health issue; and at an output device associated with the subject, promoting a therapy to the subject based upon the characterization and the therapy model.

    Method and system for fragment assembly and sequence identification

    公开(公告)号:US10255990B2

    公开(公告)日:2019-04-09

    申请号:US15811544

    申请日:2017-11-13

    申请人: uBiome, Inc.

    摘要: Embodiments of a method and/or system for improving fragment assembly and/or sequence identification includes: collecting a sample including a set of nucleic acid components associated with a set of microorganisms; generating a set of tagged sequence fragments; amplifying the set of tagged sequence fragments and sequencing the set of tagged sequence fragments; based upon the set of identifier tags, generating a set of branched assemblies of candidate sequence fragments, wherein each of the set of branched assemblies includes a set of ordered nodes and a set of branches distributed across the set of nodes; implementing a threshold criterion to reduce the set of branched assemblies to a set of branch-reduced assemblies; and identifying a set of sequences corresponding to the set of branch-reduced assemblies and/or generating an analysis informative of the set of microorganisms associated with the sample.

    Method and system for microbiome-derived diagnostics and therapeutics

    公开(公告)号:US10242160B2

    公开(公告)日:2019-03-26

    申请号:US15606874

    申请日:2017-05-26

    申请人: uBiome, Inc.

    摘要: A method for diagnosing and treating an immune microbial dysfunction in a subject, the method comprising: receiving an aggregate set of biological samples from a population of subjects; generating at least one of a microbiome composition dataset and a microbiome functional diversity dataset for the population of subjects; generating a characterization of the immune microbial dysfunction based upon features extracted from at least one of the microbiome composition dataset and the microbiome functional diversity dataset, wherein the characterization is diagnostic of at least one of Crohn's disease, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), ulcerative colitis, and celiac disease; based upon the characterization, generating a therapy model configured to correct the immune microbial dysfunction; and at an output device associated with the subject, promoting a therapy to the subject based upon the characterization and the therapy model.